Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Trial Profile

Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top